Siegfried Aktie 142932682 / CH1429326825
Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
21.08.2025 06:30:05
|
Siegfried on track to deliver profitable growth
Siegfried AG / Key word(s): Half Year Results Media Release Ad hoc announcement pursuant to Art. 53 Listing Rules In the first half of 2025, Siegfried (SIX: SFZN) successfully executed its strategy and continued to grow profitably. As expected, the seasonality between the half years is stronger in 2025 compared to previous years. Performance was supported by strong demand for development and manufacturing services for both drug substances and drug products across multiple markets. Profitability further increased, despite inflationary pressures in the U.S. and Germany, the final wave of customer de-stocking, and adverse currency developments. Over CHF 35 million of cash was released as a result of ongoing networking capital optimization, despite a significant increase in inventories for ongoing manufacturing that will convert into revenues in the second half of the year. Execution of the EVOLVE+ strategy remains firmly on track, sharpening Siegfried’s focus on Commercial, Development, and Operational excellence, while laying the foundation for future value creation through targeted M&A. Marcel Imwinkelried, Chief Executive Officer: "In the first half of the year, Siegfried delivered according to plan, laying a solid foundation which allows us to confirm our 2025 outlook. This reflects the strength of our diversified customer base and our efficient operations. The execution of our strategy EVOLVE+ is making rapid progress, setting the course to outpace market growth across the key segments we are operating in and further strengthening our position as a leading CDMO in the pharmaceutical industry." Net sales amounted to CHF 619.5 million, an increase of 1.6% in local currencies (-0.1% in Swiss Francs). The Drug Substances cluster contributed CHF 413.8 million, an increase of 2.1% in local currencies (0.6% in CHF), while Drug Products generated CHF 205.8 million in net sales, an increase of 0.7% in local currencies (-1.5% in CHF). Core EBITDA amounted to CHF 133.9 million (prior period: CHF 132.1 million), resulting in an increased Core EBITDA margin of 21.6% (prior period: 21.3%). Core net profit amounted to CHF 65.7 million (prior period: CHF 71.7 million). This decrease is caused by negative exchange rate differences which reflect a point-in-time view. Cash flow from operating activities increased to CHF 149.6 million (prior period: CHF 118.9 million). Strategic expansions focusing on growth opportunities Outlook confirmed Half-Year Results 2025
About Siegfried Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services. expect more Siegfried AG End of Inside Information |
Language: | English |
Company: | Siegfried AG |
Untere Brühlstrasse 4 | |
4800 Zofingen | |
Switzerland | |
Phone: | +41 62 746 11 11 |
E-mail: | info@siegfried.ch |
Internet: | https://www.siegfried.ch |
ISIN: | CH1429326825 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 2186524 |
End of Announcement | EQS News Service |
|
2186524 21-Aug-2025 CET/CEST
Nachrichten zu Siegfried Holding AG
26.09.25 |
Siegfried-Aktie im Plus: VRP Andreas Casutt tritt 2026 zurück - Beat Walti vorgeschlagen (AWP) | |
26.09.25 |
Change in the Chairmanship of the Board of Directors (EQS Group) | |
11.09.25 |
Siegfried successfully places senior bonds of CHF 300 million (EQS Group) | |
21.08.25 |
Siegfried-Aktie unter Druck: Siegfried bleibt trotz geringem Wachstum bei Prognose (AWP) | |
21.08.25 |
Siegfried on track to deliver profitable growth (EQS Group) | |
17.07.25 |
Siegfried-Aktie schwächer: Stühlerücken in der Geschäftsleitung (AWP) | |
23.05.25 |
Siegfried-Aktie tiefer: Siegfried erweitert spanische Produktionsstätte für Augentropfen (AWP) |
Analysen zu Siegfried Holding AG
Let’s talk about Börsenjahr 2025 | Börsentag Zürich 2025
Ein besonderes Highlight des Börsentag Zürich 2025 war die grosse Diskussionsrunde mit:
👉 Thomas B. Kovacs (Sparkojote)
👉 Robert Halver (Baader Bank)
👉 Tim Schäfer (Finanzblogger, New York)
👉 Lars Erichsen (Börsencoach & YouTuber)
👉 David Kunz (COO, BX Swiss)
Gemeinsam analysieren sie die Entwicklungen an den Finanzmärkten 2025, teilen Einschätzungen zu aktuellen Trends und geben spannende Einblicke für Anleger.
📌 Themen im Fokus:
🔹Welche Krisen & geopolitischen Risiken beschäftigen die Märkte wirklich?
🔹Wie wirken sich Zölle speziell auf die Schweiz und ihre Exportwirtschaft aus?
🔹Zinspolitik: Unterschiede zwischen USA, Europa und Schweiz.
🔹Aktien vs. Immobilien: Welche Assetklasse lohnt sich 2025 mehr?
🔹Künstliche Intelligenz – Hype oder langfristiger Wachstumstreiber?
🔹Gold vs. Bitcoin: Welches Asset ist der bessere Schutz im Depot?
🔹Inflation, Liquidität und Notenbanken: Warum Sachwerte profitieren.
🔹Blick in die Glaskugel: Wo stehen Aktien & Krypto Ende 2025?
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Möglicher US-Shutdown im Blick: SMI vorbörslich wenig bewegt -- DAX-Anleger dürften sich zurückhalten -- Asiens Börsen entwickeln sich unterschiedlichAm heimischen Aktienmarkt ist die Richtung zunächst unklar. Auch am deutschen Aktienmarkt dürfte Zurückhaltung den Handelsauftakt prägen. In Fernost ist keine einheitliche Richtung zu erkennen.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |